cARDIOPROTECTION BY BIMYO

Protect Infarct Patients from Heart Failure

Scroll Down

Save The Cardiac Function Through The Protection Of Mitochondria

  • Despite decades of effort, cardiovascular damage, particularly from myocardial infarction and cancer treatments, will be the leading cause of death worldwide in 2022.
  • That’s why Bimyo is pioneering B-017, a highly effective peptide without side effects at the end of the pre-clinical stage. We strive for patients to get access to B-017 from 2026 onwards!
  • We believe we have the potential to protect patients suffering from myocardial infarction and cancer therapy-related cardiotoxicity and reduce healthcare costs.
WHO WE ARE

Developing breakthrough treatment options for Myocardial Infarction

Prevalence
Product
Team

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas elit sem, consequat sed turpis vel, volutpat pharetra lectus. In in bibendum ante. Sed faucibus odio in porttitor volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

7 millions Patients Y/Globally
1 Patient Every 40s / USA
10% Mortality

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas elit sem, consequat sed turpis vel, volutpat pharetra lectus. In in bibendum ante. Sed faucibus odio in porttitor volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

Product
Science
Team

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas elit sem, consequat sed turpis vel, volutpat pharetra lectus. In in bibendum ante. Sed faucibus odio in porttitor volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

Team
Product
Science

Prevalence

Myocardial Infarction

7 Million Patients / Year
Globally
1 Patient Every 40s
USA
10-15%
Mortality

Cancer Therapy-Related Cardiotoxicity

20 Million Cancer Survivors
USA
Survivors Of Childhood Cancers
8 fold risk Of Cardiac-Related Mortality
Mortality
>30% of cancer survivors die from cardiovascular diseases


Fast-Track From In-Human Studies To Regular Prescriptions

Enable first patients to get access to Bimyo Drug B-017 from 2026 onwards

2012
The Idea Is Born
2013-2018
Scientific Research
2019
B-017 Selection
2020-2022
In-Animal Studies
2023
IND
2023-2025
In-Human Studies
2026
Market Authorization
2026
Bimyo Approved
WHAT WE DO

First-To-Market Therapy for Cardiac Ischemic Reperfusion Injury

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas elit sem, consequat sed turpis vel, volutpat pharetra lectus. In in bibendum ante. Sed faucibus odio in porttitor volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
Company
The Founders

Team of highly committed experts in the field of Cardioprotection

Prof. Dr. Tienush Rassaf, MD

Founder

Chair, Department of Cardiology and Vascular Medicine of the West German Heart- and Vascular Center
‍
Vice-Dean of Research of the Medical Faculty, University Duisburg-Essen

Associate Prof. Dr. Ulrike Hendgen-Cotta

Founder

Head of the Cardio Science Labs of the Department of Cardiology and Vascular Medicine at the West German Heart- and Vascular Center, University Duisburg-Essen

PhD in Biology,
University of Düsseldorf

Dr. Axel Heinemann

Managing Director

20 years BCG, Senior Partner
& Member of the
Global Health Care Group

PhD in Biotechnology,
University Hohenheim

Objective:
Protection of Mytochondria

B-017 is a novel peptide capable of preventing mitochondrial damage to save hear issue in Myocardial Infraction and Cancer therapy-related Cardiotoxicity.

Learn More
CONTACT US

Reach out to learn more.

We don’t share your data.  View Privacy Policy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Bimyo GmbH, Alfred-Nobel-Strasse 10, 40789 Monheim, Germany;  Managing Director Dr. Axel Heinemann, HRB 94801 Commercial Register Düsseldorf (Germany)

Telephone +49 170 334 3253
E-Mail a.heinemann@bimyo.de